Late Monday, Arvinas Inc. was forced to divulge the contents of its upcoming breast cancer data presentation, slated for the 2022 San Antonio Breast Cancer Symposium (“SABCS”). The clinical-stage biopharma was originally set to unveil the Phase II data for its lead breast cancer medication, ARV-471, on Dec. 8, 2022. But Arvinas’ and Pfizer’s joint abstract was inadvertently published early for conference participants by SABCS. Arvinas’ stock price has since fallen by 18% over the first two days of the holiday-shortened week.
Researchers from the University of Washington have developed an investigational vaccine that can safely elicit an immune response against the HER2 protein, a key marker in breast cancer.
The company said its experimental drug capivasertib was able to help patients with an advanced form of breast cancer live longer, when combined with the drugmaker’s older cancer treatment Faslodex regardless of biomarker status.
For all its forays elsewhere, diabetes remains the bedrock of Lilly’s business – and, if the Mounjaro launch goes as hoped, will continue to be so for a long time to come.
A strong product pipeline and increased group sales confirm that Roche is on the right growth path.
Young adults are conducting a new kind of breast cancer check thanks to Young Survival Coalition, Lizzo’s shapewear brand YITTY, and OHG’s Purpose Group, made up of Patients & Purpose and Science & Purpose.
The European Commission is set to propose boosting regular screenings for cancer and expanding them to additional types of tumors, after check-ups fell dramatically during the COVID-19 pandemic, EU officials said on Wednesday.
The drug received priority review and breakthrough therapy designations for the indication, and approval was granted to Daiichi Sankyo four months ahead of the Prescription Drug User Fee Act deadline.
Bias in healthcare, and what we can do about it.
Gilead Sciences shared what seemed to be good news regarding Trodelvy in HR+/HER2- breast cancer at the 2022 American Society of Clinical Oncology’s annual meeting, but a modest survival advantage left some wondering about the clinical significance.